文献速递头颈与中枢神经肿瘤

唾液腺黏液表皮样癌的综合基因组分析揭示频发的BAP1、PIK3CA及其他可靶向基因组改变

Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations.
PubMed 文献 · Ann Oncol · 2017-01-01

研究对48例唾液腺黏液表皮样癌行315个癌症相关基因的综合基因组分析并计算肿瘤突变负荷。结果显示高分级肿瘤基因组改变数多于低/中分级,PI3K/mTOR通路激活在高分级更常见,BAP1和BRCA1/2改变亦被检出。作者认为这些多样的改变可能为这类罕见肿瘤提供个体化治疗选择。

要点

  • 高分级肿瘤基因组改变数(均值5±3.8)多于低分级(2.3±1.4)和中分级(2.6±1.5)(P=0.019)。
  • PI3K/mTOR通路激活在高分级占52%,高于低/中分级的4.3%(P=0.007)。
  • BAP1改变见于20.8%肿瘤,BRCA1/2改变见于10.5%,ERBB2扩增仅8.3%。

核心结论

  • 唾液腺黏液表皮样癌的综合基因组分析显示多样的基因组改变,可能为这类罕见肿瘤患者带来个体化治疗选择。

研究设计与样本

  • 从48例黏液表皮样癌提取DNA,对315个癌症相关基因及28个常重排基因的内含子行杂交捕获接头连接文库的综合基因组分析,并计算肿瘤突变负荷,评估所有类型基因组改变。

主要发现

  • 共在80个独特基因中发现183个基因组改变。
  • 高分级肿瘤基因组改变数(均值5±3.8)多于低分级(2.3±1.4)和中分级(2.6±1.5)(P=0.019)。
  • TP53改变见于所有分级(41.7%),在高分级恶性肿瘤中最常见(56%)(P=0.047)。
  • CDKN2A改变见于41.6%的肿瘤。
  • PI3K/mTOR通路激活(包括PIK3CA突变)在高分级占52%,高于低/中分级的4.3%(P=0.007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to identify genomic alterations (GAs) in salivary mucoepidermoid carcinomas. PATIENTS AND METHODS: DNA was extracted from 48 mucoepidermoid carcinomas. Comprehensive genomic profiling (CGP) including the calculation to tumor mutational burden (TMB) was performed on hybridization-captured adaptor ligation-based libraries of 315 cancer-related genes plus introns from 28 genes frequently rearranged for cancer and evaluated for all classes of GAs. RESULTS: A total of 183 GAs were found in 80 unique genes. High-grade tumors had more GAs (mean 5 ± 3.8) compared with low (2.3 ± 1.4) or intermediate (2.6 ± 1.5) (P = 0.019). TP53 GAs were seen in all tumor grades (41.7%) but were most common in high-grade malignancies (56%) (P = 0.047). CDKN2A GAs were seen in 41.6% of tumors. PI3K/mTOR pathway activation, including PI3KCA mutations, were more common in high grade (52%) than in low- and intermediate-grade tumors (4.3%) (P = 0.007). BAP1 GAs were observed in 20.8% of tumors and BRCA1/2 GAs present in 10.5% of specimens. ERBB2 amplifications were seen in only 8.3% of tumors. The TMB for this patient group was relatively low with only 5 (10%) of cases having greater than 10 mutations/megabase of sequenced DNA. CONCLUSION: CGP of salivary mucoepidermoid carcinomas revealed diverse GAs that may lead to customized treatment options for patients with these rare tumors.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wang K, McDermott JD, Schrock AB, et al. Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. Ann Oncol. 2017. PMID: 28327999. doi:10.1093/annonc/mdw689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。